Lemborexant

🧮 Dose calculator

Insomnia · Regimen source: FDA Dayvigo · 2.1

• • No more than once a night, ≥7 h before awakening. Moderate/strong CYP3A inhibitors or inducers: avoid; weak inhibitors: max 5 mg. Moderate hepatic impairment max 5 mg; severe not recommended. FDA Dayvigo · 2.1FDA Dayvigo · 2.2FDA Dayvigo · 2.3

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyUse with caution

  Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Dayvigo · 8.1

  “Risk Summary There are no available data on DAYVIGO use in pregnant women to evaluate for drug-associated risks of major birth defects, miscarriage or adverse maternal or fetal outcomes.”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Dayvigo · 8.2

  “Risk Summary Available data from a lactation study in 8 women indicates that lemborexant is transferred into the breastmilk of nursing mothers, and the results have established a mean daily infant dose of 0.0029 mg/kg/day and a relative infant dose of less than 2% of the maternal dose.”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Dayvigo · 8.4

  “The safety and effectiveness of DAYVIGO have not been established in pediatric patients.”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Dayvigo · 8.5

  “Because DAYVIGO can increase somnolence and drowsiness, patients, particularly the elderly, are at a higher risk of falls [see Warning s and Precautions ( 5.1 )] .”

• ⚥ Females & males of reproductive potentialNo data

  The source for this drug has no section for this group.